Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.63 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | LPL | P06858 | 7/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299031 | 0.86 | ENPP2 (0.57) | ENPP2PSIP1GAALPLLIPG | |
| SCHEMBL19213881 | 0.85 | PSIP1 (0.56) | ENPP2PSIP1GAALPLLIPG | |
| SCHEMBL29953691 | 0.83 | CA2 (0.55) | ENPP2PSIP1LPLLIPGCA2 | |
| SCHEMBL10455034 | 0.81 | PSIP1 (0.74) | PSIP1GAACA2HSD11B1 | |
| SCHEMBL17394192 | 0.80 | ENPP2 (0.55) | ENPP2PSIP1LPLLIPGCA2 | |
| SCHEMBL28540904 | 0.79 | RORC (0.68) | — | |
| SCHEMBL521495 | 0.78 | PSIP1 (0.52) | ENPP2PSIP1GAALPLLIPG | |
| SCHEMBL15794004 | 0.78 | GABRA2 (0.45) | ENPP2PSIP1 | |
| SCHEMBL17394071 | 0.77 | ENPP2 (0.52) | ENPP2GAALPLLIPGCA2 | |
| SCHEMBL1962408 | 0.77 | ENPP2 (0.52) | ENPP2GAALPLLIPGCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1483261-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004048345-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
| WO-2004016606-A1 | PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004013135-A1 | 2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | ENPP2 4570/4885PSIP1 2088/4885GAA 337/4885 |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ENPP2 943/4885PSIP1 3555/4885GAA 1759/4885 |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | ENPP2 2642/4885PSIP1 1248/4885GAA 1943/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | ENPP2 153/4885PSIP1 2690/4885GAA 2582/4885 |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | ENPP2 22/4885PSIP1 3810/4885GAA 1094/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | ENPP2 3144/4885PSIP1 3234/4885GAA 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.